Brown University

Antagonistic effect of aspartate-β-hydroxylase on chemotherapeutics in cholangiocarcinoma

Description

Abstract:
Bile duct cancer, known as cholangiocarcinoma (CCA), is a rare but highly aggressive cancer with a 3% incident in all gastrointestinal cancers. The only known curative treatment for CCA is surgical resection at an early stage, however, CCA is usually asymptomatic until advanced local or metastatic stages where surgical resection may not be considered curative or possible therapy. Aspartate-β-hydroxylase (ASPH) is a type 2 transmembrane protein that is frequently found to be upregulated in a number of cancers including CCA. The expression of ASPH has been associated with a poorer prognosis and a worse response to chemotherapy. Here, we examine the role of ASPH in chemotherapy and how it influences the DNA damage response.
Notes:
Thesis (Sc. M.)--Brown University, 2019

Access Conditions

Rights
In Copyright
Restrictions on Use
Collection is open for research.

Citation

Cao, Kevin, "Antagonistic effect of aspartate-β-hydroxylase on chemotherapeutics in cholangiocarcinoma" (2019). Molecular Pharmacology, Physiology, and Biotechnology Theses and Dissertations. Brown Digital Repository. Brown University Library. https://doi.org/10.26300/e9nv-a670

Relations

Collection: